Pharma M&A fuels more hedge fund returns; Fabry market set to almost double;

@FiercePharma: Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: ICYMI last week: Aprecia is building $25M plant where it will do 3D printing of drugs. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Orexigen picks up new trial tab to settle Contrave dispute with partner Takeda. More | Follow @CarlyHFierce

> Pharma deals, including AbbVie's ($ABBV) deal for Pharmacyclics and Valeant's ($VRX) buyout of Salix Pharmaceuticals, are boosting returns at hedge funds betting on M&A. Report

> The market for Fabry Disease drugs will mushroom to $1.25 billion by 2024 from $683 million last year as awareness and diagnosis improve, GlobalData says. Report

> At-risk patients say they are having trouble persuading their doctors to prescribe Gilead Sciences' ($GILD) Truvada as a preventive against HIV, despite the FDA's approval for that use. Report

> A new Senate bill expanding protection for whistleblowers could make life more difficult for pharma companies looking to comply with antitrust laws. Report

Medical Device News

@FierceMedDev: UPDATED with interview of CEO: TAVR maker JenaValve receives $26.5M to fund U.S. studies. Report | Follow @FierceMedDev

@VarunSaxena2: Crowdsourcing challenge winner looking to commercialize NIH tech to diagnose brain cancer. Article | Follow @VarunSaxena2

@EmilyWFierce: Congress urges feds to probe FDA over morcellator safety concerns. More | Follow @EmilyWFierce

> Bill introduced to fix FDA's combination product regs; attorneys say it doesn't go far enough. Story

> Sisu to put emergency blood recycling device through trials later this year. Article

Biotech News

@FierceBiotech: AstraZeneca offers $727M package to partner with Inovio on immuno-oncology. News | Follow @FierceBiotech

@JohnCFierce: Sanofi takes another stab at cancer with Evotec, Apeiron checkpoint partnership. Article | Follow @JohnCFierce

@DamianFierce: Like most people, I'm waiting for Thug_BioAnalyst to weigh in before I form an opinion on anything this morning. | Follow @DamianFierce

> Karyopharm tanks as sepsis scares plague its cancer contender. Article

> Sorrento's biotech buyouts bag CAR-T drugs. Item

> Gates backs a $120M breakout round for CRISPR/Cas9 pioneers at Editas. Story

Animal Health News

> Aratana continues to trim losses in Q2 as it focuses on animal treatments. News

> Merck to partner with National Milk Producers group on training and animal care. Report

> USDA grants conditional license to Zoetis for canine anti-itch therapy. Story

> Feds indict four with smuggling bogus pet products into the U.S. Item

> Dechra to buy control of Croatian animal vaccine maker for $56.4M. Article

Biotech IT News

> Apple's ResearchKit goes global as heart study expands into Hong Kong and U.K. Item

> IBM makes $1B bid for Merge to bolster Watson's image analytics capabilities. Report

> Teva buys majority stake in Immuneering to access genome analysis tools. More

> Illumina strikes deal to buy LIMS provider GenoLogics. Article

> FDA makes its first approval of a 3D-printed drug. Story

Pharma Marketing News

> Allergan plots Namzaric DTC campaign to shore up its Namenda defenses. Item

> Amarin case could unleash a flood of off-label promos. Report

> Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. More

> Xtandi marketer Astellas scrums with rugby partners for prostate cancer awareness. Story

> Big Pharma feeds controversy by routing big bucks to private CME. Article

And Finally... Amid consumer worries over their safety, Johnson & Johnson ($JNJ) and Colgate/Palmolive are phasing out microbeads from their personal care products. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.